TCT 2023 Late-Breaking Science Collection

Published: 09 January 2024

  • Views:

    Views Icon 250
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations. 

Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data. 

About the episode

TCT 23 - We are joined by Dr Kendra Grubb (Emory School of Medicine, Atlanta, GA, US) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on interventional science concerning structural heart disease and clinical practice.

 

Trials covered in detail include:


PARTNER 3 & EVOLUT Low-Risk
ALIGN-AR
TENDYNE
APOLLO
TRILUMINATE

 

Recorded remotely from Georgia, 2023.

Editor: Jordan Rance
Video Specialist: Dan Brent

Faculty Biographies

Kendra J Grubb

Kendra J Grubb

Surgical Director

Dr Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. She is also an associate professor of surgery at Emory University School of Medicine.

Kendra is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centred approach to the treatment of cardiovascular disease.

Her clinical interests include valve repair or replacement, coronary artery bypass graft surgery (CABG), transcatheter aortic valve replacement (TAVR) and hybrid coronary revascularization.

Dr Grubb research interests are innovative cardiac surgery technologies. She has led and participated in multiple clinical trials of innovative cardiac surgery technologies, including studies of transcatheter aortic valve replacement (TAVR), MitraClip percutaneous therapy and the GORE® conformable TAG® thoracic endoprosthesis for the primary treatment of…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.